Results 1 to 10 of about 73,019 (188)

Itch and Janus Kinase Inhibitors

Acta Dermato-Venereologica, 2023
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han, Yu Ri Woo, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim   +4 more
doaj   +3 more sources

Janus Kinase Inhibitors and Cell Therapy [PDF]

Frontiers in Immunology, 2021
Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions.
Amer Assal, Markus Y. Mapara, Markus Y. Mapara   +2 more
doaj   +3 more sources

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
doaj   +3 more sources

Janus kinase inhibitors: between prescription authorization and reimbursability

Reumatismo, 2023
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli, F. Conti, R. Caporali, F. Iannone, F. Cacciapaglia, on behalf of the Steering Committee of the Italian Society of Rheumatology   +5 more
doaj   +5 more sources

Janus kinase inhibitors in immunoinflammatory rheumatic diseases

Терапевтический архив, 2022
Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology the restoration of the ...
Evgeny L. Nasonov
doaj   +3 more sources

Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis [PDF]

Open Medicine
This meta-analysis evaluates Janus Kinase (JAK) inhibitors’ efficacy and safety in large vessel vasculitis (LVV), encompassing Giant Cell Arteritis (GCA) and Takayasu’s Arteritis (TAK).
Bai Yang, Wang Zhe, Zhang Chunling
doaj   +2 more sources

Janus kinase inhibitors: jackpot or potluck?

Oncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat, Shripad Brahmanand Pande   +1 more
doaj   +3 more sources

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives [PDF]

Psoriasis: Targets and Therapy, 2019
Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence ...
Ly K, Beck KM, Smith MP, Orbai AM, Liao W   +4 more
doaj   +2 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

Farmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska, Karolina Żurawska, Maciej Arciszewski, Arnold Kukowka, Bolesław Banach   +4 more
doaj   +1 more source

Intraocular infections following biologicals and Janus Kinase inhibitors [PDF]

Indian Journal of Ophthalmology
Parthopratim Dutta Majumder, Rakshita Deepak Kene   +1 more
doaj   +2 more sources